Emergent BioSolutions repurchases USD 75 million of senior unsecured notes due 2028
EBS•Refinancing plans
Emergent BioSolutions said it is evaluating the timing to refinance the remaining Senior Unsecured Notes maturing in August 2028.
Remaining debt balance and liquidity
Following the transaction, the outstanding aggregate principal balance of the Senior Unsecured Notes was reduced to about USD 364.7 million.
The company said liquidity included a strong cash position and access to an additional USD 50 million under an asset-based revolving facility.
Repurchase of senior unsecured notes
Emergent BioSolutions completed a repurchase of USD 75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028.
The company said it deployed about USD 68 million in cash, with an average repurchase price of 90.6% of face value.
